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Induced pluripotent stem cells (iPSCs) outwardly
appear to be indistinguishable from embryonic
stem cells (ESCs). A study of gene expression
profiles of mouse and human ESCs and iPSCs
suggests that, while iPSCs are quite similar to their
embryonic counterparts, a recurrent gene expres-
sion signature appears in iPSCs regardless of their
origin or the method by which they were generated.
Upon extended culture, hiPSCs adopt a gene
expression profile more similar to hESCs; however,
they still retain a gene expression signature unique
from hESCs that extends to miRNA expression.
Genome-wide data suggested that the iPSC signa-
ture gene expression differences are due to differen-
tial promoter binding by the reprogramming factors.
High-resolution array profiling demonstrated that
there is no common specific subkaryotypic alteration
that is required for reprogramming and that repro-
gramming does not lead to genomic instability.
Together, these data suggest that iPSCs should be
considered a unique subtype of pluripotent cell.
INTRODUCTION
Embryonic stem cells (ESCs) are in vitro representations of the
inner cell mass of developing embryos (Gokhale and Andrews,
2006) and therefore present a valuable tool for regenerative
medicine and serve as models of embryonic development
in vitro (Keller, 2005). Induced pluripotent stem cells (iPSCs)are not derived from embryos but are in vitro constructs thought
to mimic ESCs (Hochedlinger and Plath, 2009; Nishikawa et al.,
2008; Takahashi and Yamanaka, 2006). Therefore, a number of
issues must be addressed before iPSC technology can be
applied to regenerative medicine or in vitro modeling of disease
or development. Are iPSCs as good as ESCs at replicating the
state of bona fide embryonic cells? Do iPSCs generate differen-
tiated progeny as efficiently as ESCs?Do themethods employed
to generate iPSCs confound their use in a clinical or experimental
setting? These questions should be at the forefront when consid-
ering whether iPSCs will serve as useful models of human devel-
opment and disease. However, before these questions can be
answered, it is critical to understand any molecular differences
between iPSCs and ESCs in their undifferentiated state.
Even though many groups have now shown that both human
(h) and mouse (m) somatic cells can be reprogrammed by over-
expression of variable sets of a few transcription factors to what
appears to be an embryonic state (Lowry et al., 2008; Maherali
et al., 2007; Wernig et al., 2007; Okita et al., 2007; Park et al.,
2008; Takahashi et al., 2007; Takahashi and Yamanaka, 2006;
Yu et al., 2007), the degree ofmolecular similarity between iPSCs
and ESCs has not been completely elucidated. Every study
suggests that iPSCs are ‘‘nearly identical’’ to their embryo-
derived counterparts, but it remains unclear whether the small
percentage of genes that are differentially expressed between
iPSCs and ESCs are shared among different iPSC lines and
whether this difference is biologically significant. Careful study
is warranted to discern whether these small differences
observed between iPSC and ESC lines are particular to indi-
vidual experiments or whether reprogramming of somatic cells
generates a state that is common among iPSCs and unique
from ESCs. Because of the methods used to reprogram somatic
cells to an embryonic state, iPSCs could possess significantCell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 111
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Expression Signatures Distinguish iPSCs from hESCsFigure 1. Expression Profiling Demonstrates Differences between hiPSCs and hESCs
(A) Unsupervised hierarchical clustering of global gene expression data in human fibroblasts (hFibr), early-passage hiPSCs (e-hiPSC), late-passage hiPSCs
(l-hiPSC), and hESCs. Expression values are presented as the log2 ratio of the given gene divided by the average of the ESC lines (all subsequent expression
heatmaps are presented in this manner). Individual cell lines used are indicated below the heatmap.112 Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc.
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Expression Signatures Distinguish iPSCs from hESCsdifferences at various molecular levels, including the following:
genomic integrity; epigenetic stability; noncoding, and perhaps
even coding, RNA expression. To date, no one has described
the full extent of differences between iPSCs and ESCs, and
whether these differences are shared among reprogrammed
lines derived by various methods and labs.
Here, we applied genome-wide methods to compare mouse
andhuman iPSCswith ESCsbyarrayCGH, to uncover subkaryo-
typic genome alterations; coding RNA profiling, to uncover gene
expression changes; miRNA profiling, to determine changes in
expression of small noncoding RNAs; and histone modification
profiling, to determine whether epigenetic changes correlate
with gene expression differences. The sum of these analyses
uncovers a novel gene expression signature that is unique
from ESCs and shared among iPSC lines generated from
different species and in different reprogramming experiments.
Whether the iPSC signature described here plays a functional
role in self-renewal or differentiation warrants extensive further
investigation.
RESULTS
Distinct Gene Expression Signatures Are Associated
with hiPSCs at Different Passages
To determine whether gene expression differences observed
between ESCs and iPSCs are stochastic or indicative of differ-
ences between these pluripotent cells types, a detailed genome-
wide expression analysis was carried out between three hESC
lines that we routinely maintain in the lab (HSF1, H9, and CSES4)
and hiPSC clones at different passages (Table S1, a summary of
cell lines and passages used in this study, is available online). The
hiPSC clones used here were obtained in a single fibroblast
reprogramming experiment published previously (Lowry et al.,
2008) through retroviral expression of OCT4, SOX2, NANOG,
KLF4, and C-MYC. Five hiPSC clones (#1, 2, 5, 7, and 18), two
of which had integrated the NANOG virus in addition to the other
four factors (clones1and5),wereexpanded for further analysis of
pluripotency, including teratoma formation and in vitro differenti-
ation (Karumbayaram et al., 2009; Lowry et al., 2008; Park et al.,
2009). These clones were all profiled at early passage (passages
[p] 5–9) and clones 1, 2, and 18 were also analyzed at late
passage (p54–61). Unsupervised hierarchical clustering of the
expression data across hESCs, early- and late-passage hiPSCs,
and fibroblasts highlighted interesting patterns of gene expres-
sion between these cell types (Figure 1A). First, even though
hiPSCs are considered highly similar to hESCs, they are more
similar to each other than to hESCs, as shown previously (Lowryet al., 2008). Second, late-passage hiPSCs cluster more closely
with hESCs than with early-passage hiPSCs. In agreement with
these findings, Pearson correlation analysis also demonstrated
that the gene expression profile of late-passage hiPSCs is more
closely related to hESCs than to early-passage hiPSCs using
Fisher’s z0-transformation comparison of correlations (z = 0,
Figure S1).
A Unique Expression Signature for Early-Passage
hiPSCs
Analyzing the expression differences between hESC lines and
our early-passage hiPSC lines, we found 3,947 (out of 17,620)
genes that are significantly different between all hiPSC lines
and hESC lines as determined by a Student’s t test (p < 0.05)
and requiring an at least a 1.5-fold expression change between
hiPSCs and hESCs (Figure 1B; termed early-passage hiPSC
signature genes; Table S2). Since these expression differences
to hESCs are shared among all five independent hiPSC clones,
the data suggest that hiPSCs represent a common cell type
that is similar to but distinct from hESCs. Within this expression
signature, 79% of the genes are expressed at a lower level in
iPSCs than ESCs (Figure 1B0). Gene Ontology analysis suggests
that these genes have a role in basic processes (energy produc-
tion, RNA processing, DNA repair, mitosis), while genes related
to differentiation (organ development and signal/secreted glyco-
protein) are more abundantly expressed in hiPSCs than ESCs
(Figure 1B00 0).
These findings suggest that hiPSCs have not efficiently
silenced the expression pattern of the somatic cell from which
they are derived and failed to induce genes important for undif-
ferentiated, highly proliferative hESCs. Indeed, a classification
of the early-passage hiPSC signature genes according to their
expression difference between fibroblasts and hESCs shows
that 82% of the genes that are expressed at a higher level in
hESCs versus hiPSCs are also more highly expressed in hESCs
versus fibroblasts (Figure 1B0), indicating that an important differ-
ence between hESC and early-passage hiPSCs is the lack of the
complete induction of these genes. When analyzing the genes
with more abundant transcripts in early-passage hiPSC than
hESCs, 71% appear to be inefficiently silenced from the fibro-
blast state (Figure 1B0). The remaining smaller portion of early
hiPSC signature genes can be explained by excessive induction
of an ESC-specific expression program or suppression of the
fibroblast pattern (Figure 1B0).
While the expression differences between early-passage
hiPSC and hESC lines appear to be reprogramming dependent,
one obvious explanation for the difference could be that we(B) e-hiPSC signature genes. As in (A) except for the 3947 genes significantly different between e-hiPSC and hESCbased on two criteria, Student’s t test (p < 0.05)
and at least a 1.5-fold change. Genes are ordered according to the decreasing average expression ratio between hESCs and e-hiPSCs. Expression data for
passage 5 and 28 hESC (P5 and P28) for this set of genes are added to the right. (B0) e-hiPSC genes were divided into those expressed at higher levels in hESCs
than e-hiPSCs and vice versa. Each of these two groupswas further subclassified into two groups, either more highly expressed in hESCs than fibroblasts (red) or
more highly expressed in fibroblasts than hESCs (blue). (B00) Boxplots of the absolute value of the log2 fold change between hESC and the following: e-hiPSC,
l-hiPSC, P5 or P28 hESC (*all p = 0). (B00 0) Gene ontology (GO) analysis for e-hiPSC signature genes upon division into those for which hESC expression was
greater than e-hiPSC and vice versa. Only significant GO-terms with an enrichment value >3 (p < 0.001) are presented.
(C) l-hiPSC signature genes. As in (B) except for the 860 genes significantly different between hESCs and late-passage-hiPSCs. (C0) Barplot similar to (B0) using
l-hiPSC signature genes. (C00) Boxplot similar to (B00) for l-hiPSC signature genes.
(D) Common hiPSC signature genes were determined as the overlap between early- and late-passage signature genes from (B) and (C), respectively, as shown in
the Venn diagram. The expression heatmap below is presented for the 318 genes in the overlap as in (B). (D0) Barplot similar to (B0) using common hiPSC signature
genes. (D00) Boxplot similar to (B00) for common hiPSC signature genes.Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 113
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(p37, 41, and 51) since the availability of hESCs at early
passage is limited. Thus, the distinct expression pattern of
early-passage hiPSCs versus late-passage hESCs could simply
be due to differences induced by extended culturing. To estimate
the contribution of culture-induced transcriptional changes, early
(p5)- and middle (p28)-passage hESCs were obtained, profiled,
and compared to our cell lines. This analysis suggested that
the vast majority of the genes consistently differentially ex-
pressed between early-passage hiPSCs and hESCs do not
differ dramatically between early-, middle-, and late-passage
hESCs (Figure 1B, far right, and Figure S2). Together, these
data indicate that the early-passage hiPSC signature is not
a common feature of low-passage pluripotent stem cells but is
specific to hiPSCs.
Expression Differences between Early- and
Late-Passage hiPSCs
Upon extended passaging, the gene expression profile of
hiPSCs appears to become more similar to hESCs (Figures 1A,
1B, and S1). In agreement with this conclusion, late-passage
hiPSCs have a significantly decreased amplitude of expression
differences for early-passage hiPSC signature genes (Figures
1B00and S3A). As expected, the same was true when comparing
early-, middle-, and late-passage hESCs (Figure 1B00). Looking at
48 genes that are specifically expressed in hESCs (taken from
Lowry et al., 2008), it is clear that hESC signature genes are
expressed at lower levels in all early hiPSC lines but recover after
extended culture to a level commensurate with that found in
hESCs (Figure S4). These data indicate that many of the expres-
sion differences that occur between early-passage hiPSCs and
hESCs get resolved upon extended passaging.
However, Figure 1A shows that late-passage iPSC still differ
from ESCs. The differential expression between late-passage
hiPSCs and hESCs of some of these genes was validated at
the protein level (Figure S5). We therefore defined genes that
are differentially expressed more than 1.5-fold between late-
passage hiPSCs and hESCs and found 860 genes that fit these
criteria (Figure 1C; termed late-passage hiPSC signature genes;
Student’s t test, p < 0.05; Table S3). Gene ontology analysis
failed to uncover enrichment for any particular functional cate-
gory among late-passage hiPSC signature genes, in agreement
with the finding that at late passage the majority of expression
differences of hiPSCs with hESCs that exist at early passage
are resolved. Comparing fibroblast, hESC, and hiPSC expres-
sion, we found that 80% of the late-passage hiPSC signature
can be attributed to inefficient silencing of the fibroblast expres-
sion pattern and lack of full induction of hESC-specific genes,
similar to what was found for the early-passage hiPSC gene
expression signature (Figure 1C0). In agreement with this notion,
318 genes (37%) are shared between early- and late-passage
hiPSCs versus hESCs (Figure 1D; Table S4). This enduring
(also termed common) hiPSC signature is clearly a result of
differences between cells generated by the reprogramming
process versus those derived from human embryos and does
not appear to differ dramatically in expression between early
and later passages of hiPSC (Figures 1D00 and S3C). Nearly all
of the genes in this group insufficiently induce hESC-specific
genes and suppress fibroblast-specific genes (Figure 1D0).114 Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc.Furthermore, the common hiPSC signature genes exhibit the
most dramatic change in gene expression between fibroblasts
and hESCs among all signature expression groups (Figure S7).
Surprisingly, many late-passage hiPSC signature genes are
more similarly expressed between early hiPSCs and hESCs
than in late hiPSCs (Figures 1C, 1C00, and S3B). This is consistent
with the notion that an overall readjustment of the expression
signature occurs upon passaging of hiPSCs, rather than simply
closing in on the ESC expression. Taken together, the compar-
ison of hiPSC and hESC expression patterns indicates that
(1) at early passage hiPSC lines are incompletely reset to
a hESC-like expression pattern and (2) even at late passage
differences between hESCs and hiPSCs persist and reflect an
imperfect resetting of somatic cell expression to an ESC-like
state.
To exclude the possibility that gene expression differences
between hESCs and hiPSCs at late passage could be due to
differential proliferation of hiPSCs and hESCs, cell-cycle analysis
was performed by FACS. This analysis demonstrated that late-
passage hiPSCs and hESCs do not proceed through the cell
cycle at different rates, and thus the late hiPSC signature is not
due to varying proliferation capacity (Figure S6).
Conservation of the hiPSC Expression Signature across
Independent Reprogramming Experiments
Next, we determined if expression signatures observed between
established hESC lines and hiPSCs from our lab also occur in
reprogramming experiments by different labs to establish
whether these differences are shared among reprogrammed
lines derived by various methods and labs. To this end, we per-
formed a similar analysis as described above with data available
from other laboratories (NIH, Gene Expression Omnibus) and
compared the overlapping signatures with those signatures
derived from our early and late hiPSCs. In Maherali et al.
(2008), neonatal foreskin fibroblasts were reprogrammed to the
iPSC state by expressing OCT4, SOX2, KLF4, NANOG, and C-
MYC using tetracycline-inducible lentiviral vectors (Maherali
et al., 2008). Gene expression profiling from this experiment re-
vealed 1653 genes at least 1.5-fold differentially expressed
when comparing their hiPSCs to their hESCs (Figure 2). Of these,
618 overlapped with the 3947 early-passage hiPSC signature
genes found in our hiPSC clones (p < 1047; Figure 2).
The same analysis was performed with data from Soldner
et al., who reprogrammed dermal fibroblasts obtained from
patients with Parkinson’s disease using a single doxycycline-
inducible lentivirus carrying either four (OCT4, SOX2, c-MYC,
and KLF4) or three (OCT4, SOX2, and KLF4) reprogramming
factors (Soldner et al., 2009). Importantly, in this study, the
reprogramming factors were removed after establishment of
hiPSC lines because the viral sequences encoding the factors
were Cre-recombinase excisable. We found a 1.5-fold differen-
tial expression of 899 genes between their hiPSCs and their
hESCs before excision of the reprogramming factors (2lox
hiPSCs). Of these genes, 329 overlapped with our early-passage
hiPSC signature (p < 1022; Figure 2). Following Cre-mediated
depletion of the factors and subcloning of the iPSCs (1lox
hiPSCs), 553 genes remained differentially expressed following
our criteria, and 222 of these genes overlapped our early-
passage hiPSCs (p < 1020).
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Expression Signatures Distinguish iPSCs from hESCsFigure 2. Differential Expression Patterns between
hESC and hiPSC Are Conserved among Independent
Reprogramming Experiments
iPSCsignature genesdefined asgenesdifferentially expressed
between hiPSC and hESC lines (Student’s t test [p < 0.05] and
at least a 1.5-fold change) were obtained from Figure 1 of this
study (Chin et al.) and from additional published reprogram-
mingexperiments. Thematrix summarizes theoverlapofhiPSC
signature genes between the different experiments. The values
on the diagonal designate the total number of genes identified
as significantly different in expression between hESCs and the
indicated hiPSCs. The intersection of the rows and columns
give the number of genes that are in common between the
two respective experiments and the corresponding signifi-
cance (p value) as determine using Fisher’s exact test. For
the Soldner et al. experiment (Soldner et al., 2009), data were
analyzed before (2lox) and after (1lox) excision of the reprog-
ramming factors. In Yu et al. (2009), iPSCs were generated
with episomal vectors andanalyzed before (episomal) and after
subcloning. Genomic integrations were not detected for any of
these subclones. The Maherali iPSCs (Maherali et al., 2008)
were reprogrammed with integrating lentiviruses.Yu et al. reprogrammed neonatal foreskin fibroblasts using
nonintegrating episomal vectors encoding OCT4, SOX2,
NANOG, c-Myc, KLF4, LIN28, and SV40LT (episomal hiPSC)
(Yu et al., 2009). Upon continuous passaging, the episomal
vectors are lost and hiPSC subclones without any ectopic DNA
could be isolated (subcloned hiPSCs). An analysis of their
expression data again revealed a set of genes that are differen-
tially expressed between hESCs and hiPSCs and a highly signif-
icant overlap of these differentially expressed genes with those
found differentially expressed between our hiPSCs and hESCs
(Figure 2). This finding was particularly relevant not only because
the Yu et al. lines never experienced integration, but also
because the combination of reprogramming factors used
differed slightly from that in other reprogramming experiments.
These analyses described the degree of similarity of differen-
tial expression between hESCs and hiPSCs generated in inde-
pendent experiments. To determine the extent by which the
same genes are differentially regulated in the same direction
among independent experiments, a similar analysis was per-
formed with the added requirement that direction of the expres-
sion change between hESCs and hiPSCs must be conserved
in both experiments being compared. These data suggest that
many of the genes shown in Figure 2 to be differentially ex-
pressed in multiple experiments were also changed in the
same direction (Figure S8).
Further analysis to demonstrate the degree of overlap between
any three hiPSC signatures also suggests a highly significant
overlap. Between the Chin, Maherali, and Soldner signatures,
79 genes were shared (p < 1044); between the Chin, Maherali,
and Yu signatures, 106 genes were shared (p < 1096); between
Chin, Soldner, and Yu, 48 genes were shared (p < 1034). Among
all the experiments of all four laboratories, 15 genes are differen-
tially expressed between early-passage hiPSCs and hESCs (p <
1054; Table S5). The highly significant overlap between each of
all four of these completely independent reprogramming experi-
ments suggests that thehiPSCstate is not stochastic.Confirming
this conclusion, a gene ontology analysis of the genes differen-
tially expressed in the experiments from the four groups againsuggest that the signatures that arise in each reprogramming
experiment share a functional similarity (Figure S9).
Conservation of an iPSC Expression Signature between
Mouse and Human Reprogramming Experiments
To determine if the early hiPSC phenotype is specific to human
reprogramming or a general iPSC phenomenon, a comparison
of mouse iPSCs and ESCs was performed. Hierarchical clus-
tering of mESCs and different miPSC cell lines that were
obtained in a fibroblast reprogramming experiment with retrovir-
ally delivered Oct4, Sox2, Klf4, and c-Myc was performed. This
analysis demonstrated that, although highly similar, miPSCs
and mESCs also differ in their expression (Figure 3A). As with
the human reprogramming data, the sample tree of the hierar-
chical clustering revealed that mESCs andmiPSCs cluster sepa-
rately. Specifically, 1388 genes significantly differ in expression
levels between miPSCs and their embryonic equivalents as
determined by a Student’s t test (p < 0.05) and have at least a
1.5-fold difference. Many of these genes are functionally
involved in transcriptional regulation and organ development
(Figure S9B), as observed with human iPSCs signature genes.
To further assess the coregulation of genes in mouse and human
iPSC reprogramming experiments, the subsequent analysis was
limited to only those with identifiable homologs between mouse
and human transcriptomes (HomoloGene database Release 63).
Twenty-nine percent of the trimmed-down miPSC signature
genes were also differentially expressed in our early hiPSCs
(p < 107), suggesting that the iPSC state is remarkably robust
across species (Figure 3B; Table S6).
Similar to our observation with the human iPSC signature
genes, the majority of miPSC signature genes appeared to be
ESC-specific genes that were insufficiently induced and
fibroblast-specific genes that were not repressed completely
(Figure 3C). To determine whether differential regulation of target
genes by the reprogramming factors themselves could drive the
differential expression of genes between iPSCs and ESCs, we
tested whether expression differences between miPSC and
mESCs correlate with binding differences of the reprogrammingCell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 115
Cell Stem Cell
Expression Signatures Distinguish iPSCs from hESCsFigure 3. Reprogramming of Human and Mouse Fibroblasts Results in Conserved Expression Differences between ESC and iPSC
(A) Unsupervised hierarchical clustering of global gene expression data from mouse (m) ESCs, miPSCs, and mouse embryonic fibroblasts (MEFs) obtained from
the Maherali et al. data set (Maherali et al., 2007). The lines included are biological replicates of V6.5 and E14 mESC lines and of 1D4 and 2DA iPSC lines,
respectively. All log2 ratios are relative to averaged expression in mESCs.
(B) Comparison of iPSC signatures between human andmouse reprogramming experiments. Human early-passage iPSC signature genes as defined in Figure 1B
of this study (Chin et al.) andmouse iPSC signature genes defined with the Student’s t test (p < 0.05) and an at least 1.5-fold change betweenmiPSCs andmESCs
were further annotated to only include genes that have homologous partners across the two species according to the HomoloGene database, resulting in 2834
genes for the early hiPSC signature and 1018 genes for the miPSC signature. The Venn diagram shows the overlap between these two groups of genes, and
significance was determined using the Fisher’s exact test. The heatmap above displays the expression values for the 294 iPSC signature genes conserved
between mouse and human reprogramming experiments across the different cell types and species, as log2 ratio relative to the average ESC expression for
each species.
(C) Similar to Figure 1B0, miPSC signature genes were divided into those expressed at higher levels in mESCs than miPSCs and vice versa. Each of these two
groupswas further subclassified into two groups, eithermore highly expressed inmESCs than fibroblasts (red color) or thosemore highly expressed in fibroblasts
than hESCs (blue color).
(D) The heatmap depicts the log2 expression ratio between mESCs and miPSCs for miPSC signature genes ordered according to decreasing ratios. For these
genes, the binding strength (log10pXbar) of each reprogramming factor (Oct4 [O], Klf4 [K], Sox2 [S], or c-Myc [C]; data obtained from Sridharan et al., 2009) in
miPSCswas subtracted from the binding strength inmESCs. Higher binding strength inmESCs is represented in yellow and inmiPSCs in blue. The intensity of the
colors increases as differential binding increases. The Pearson correlation of the differential binding strength relative to differential gene expression is given in the
attached table.116 Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc.
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of genome-wide location data of the target genes of c-Myc, Klf4,
Sox2, and Oct4 proteins in the mESCs and miPSC lines that
were used for the expression analysis described here (Sridharan
et al., 2009). We previously reported that binding patterns of the
reprogramming factors are highly similar in iPSCs and ESCs but
that subtle differences exist, which we did not analyze further.
Reanalysis of these minor differences in binding demonstrates
that the promoter regions of those genes that are expressed at
a higher level in mESCs than miPSCs are correlated with
stronger binding by each of the reprogramming factors, particu-
larly by c-Myc and Klf4 (Figure 3D). Conversely, the promoter
regions of those genes that are expressed at a higher level in
miPSCs are correlated with stronger binding by the repro-
gramming factors in miPSCs (Figure 3D).
To determine whether the iPSC signature is specific to reprog-
ramming with fibroblasts as opposed to other cell types, this
type of analysis was extended to iPSCs generated from mouse
B cells by a different lab (Mikkelsen et al., 2008). As was shown
with fibroblast-derived miPSCs, miPSC lines made from B cells
also display a common group of genes differentially expressed
compared to mESC lines (Figure S10). The high degree of over-
lap of B cell miPSC signatures with fibroblast miPSC lines
suggests that iPSC gene expression signatures arise regardless
of the cell type of origin (522 genes, p < 1043). Furthermore,
a significant portion of the B cell miPSC signature genes are
also found to be differentially expressed in our early-passage
human iPSCs (729 genes, p < 104). Taken together, early iPSCs
possess a conserved gene expression signature that is shared
regardless of the lab of origin, species, or cell type from which
they were derived.
Global Reprogramming of Histone H3K27 Promoter
Methylation in Late-Passage hiPSCs
Perhaps as intriguing as the finding that all early hiPSCs appear
to share a common gene expression signature that sets them
apart from hESCs is the fact that this signature disappears after
extended culturing, albeit not completely. To further define at the
molecular level how similar late-passage hiPSCs are to hESCs at
similar passage, the state of histone H3 lysine 27 (K27) trimethy-
lation was analyzed, since to date the genome-wide chromatin
structure of hiPSCs has not been probed. This chromatin modi-
fication, established through Polycomb group proteins, is
repressive in nature and plays an essential role in the regulation
of the expression of many developmentally important genes
(Cao and Zhang, 2004).
Genome-wide location analysis for histone H3K27 trimethyla-
tion in human fibroblast lines, two hESCs, and two hiPSC lines
at late passage (p56, 71 for hiPSCs and p69, 64 for hESCs;
Table S1) was performed using chromatin immunoprecipitation
followed by hybridization to a human promoter array covering
regions from 5.5 kb upstream to +2.5 kb downstream of the
transcriptional start sites for about 17,000 genes. The overall
pattern of H3K27 trimethylation at promoters was very similar
among all the pluripotent stem cell lines tested and different
from the fibroblasts from which the hiPSCs were derived (data
not shown). When focusing on the promoter regions that are
differentially methylated at H3K27 between hESCs and fibro-
blasts (see Experimental Procedures), hESCs and hiPSCs arenearly identical in their methylation pattern (Figure 4A). Specifi-
cally, of the 978 genes that were identified as being different
between hESCs and fibroblasts at high stringency (p < 0.05),
97% carried a methylation pattern virtually identical in hiPSCs
and hESCs (ESC-like promoter regions in hiPSCs [E]). Pairwise
correlation analysis verified this conclusion for this set of genes
(Figure S11). Only 1% of the 978 genes were methylated in
a more fibroblast-like pattern (F class promoter regions), and
the remaining 2% of the loci were classified as neutral (N), as
the differences were too small to be significant. The distribution
remained highly similar when the stringency was lowered to
include a larger set of genes and is highly significant, as
confirmed by a random permutation test (Figure S12). Genes
that were not differentially methylated between hESC and
fibroblasts showed little or no difference in methylation pattern
in hiPSCs, indicating that the hiPSCs had not acquired a
completely novel epigenetic identity. As expected, there was
a nearly perfect inverse correlation between H3K27 trimethyla-
tion of promoters and expression of these genes in hESCs,
hiPSCs, and fibroblasts (Figure 4A).
Only 40 genes of the 860 late-passage hiPSC signature genes
and 21 genes of the enduring iPSC signature genes were found
to be differentially methylated in their promoter regions at H3K27
between fibroblasts and ESCs. However, their methylation
pattern in iPSCs is reset to the ESC state (Figures 4B and
S13). These data suggest that the aberrant expression of genes
in late-passage hiPSCs compared to hESCs is not the result of
differential H3K27 methylation between hESCs and hiPSCs.
Interestingly, early-passage miPSC are also already completely
reset in their histone H3K27 methylation patterns to the ESC
state as determined previously (Maherali et al., 2007). Together,
these results indicate that the H3K27 methylation state of the
fibroblast genome is reset almost completely to an ESC state
in iPSCs, suggesting that the early and late hiPSC gene expres-
sion signatures probably do not arise as a result of faulty
resetting of H3K27 trimethylation during reprogramming, even
though subtle differences inmethylation patterns could still exist.
In agreement with the conclusion that histone H3K27 trimethyla-
tion is not a histone mark that is aberrantly reset upon reprog-
ramming, we found that the promoter regions of early, late, or
common hiPSC signature genes undergo the same changes in
H3K27 trimethylation between hESC and fibroblasts as genes
that are equally expressed between hESCand hiPSC (Figure 4C).
A similar observation is true for H3K4 trimethylation (Figure 4D).
While there is no global correlation between these H3 modifica-
tions and hESC/hiPSC expression differences, the promoter
regions of an established set of hESC-specific genes showed
a much different pattern of histone methylation in hESCs relative
to fibroblasts for both the repressive and active histone marks
(Figures 4C, 4D, and S14), in agreement with previously pub-
lished findings (Maherali et al., 2007; Sridharan et al., 2009).
miRNA Expression Signature of the hiPSC State
It has been clearly shown that various types of cells differ not only
in the expression of their coding genes, but also in their noncod-
ing genes. To determine whether miRNAs are expressed at
a hESC-like level in hiPSCs, expression profiling of all known
miRNAs was performed on hESCs, late-passage hiPSCs, and
the fibroblasts from which they were derived (Table S1).Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 117
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Expression Signatures Distinguish iPSCs from hESCsFigure 4. Histone H3 Methylation Analysis in hiPSC
(A) Tree-view representation of the hierarchical clustering of histone H3K27 trimethylation in HSF1 (hESC1), HSF6 (hESC2), two human fibroblast lines (hFibr1 and
-2), and late-passage hiPSCs (l-hiPSC1 and l-hiPSC18) across the promoter regions of all genes considered significantly differentially methylated between fibro-
blasts and hESCs (p = 0.05). Genes were classified as E (hESC-like, 950 genes), N (neutral, 19 genes), or F (fibroblast-like, 9 genes) based on the similarity of the
methylation patterns in l-hiPSCs with hESCs or fibroblasts. For N and F class genes, the y axis is scaled 33 to make the methylation patterns visible. Each row
represents the 5.5 kb to +2.5 kb region with respect to the transcription start site (TSS). The 8 kb promoter regions are divided into sixteen 500 bp regions
displayed in pseudocolor based on the average log ratio of the IP to input probe signal intensity. Probes within a given 500 bp region are averaged. Dark
gray coloring indicates missing values for enrichment due to the lack of probes. Expression levels for the represented genes are shown on the right for hESCs,
e-hiPSCs, and l-hiPSCs relative to fibroblasts.
(B) Table showing the overlap between genes shown in (A) (which demonstrate differences in H3K27 methylation between hESCs and fibroblasts), grouped
according to the methylation pattern in l-iPSCs, and the late and common hiPSC expression signature genes as defined in Figures 1C and 1D (these genes
are differentially expressed between l-hiPSCs and hESCs). *p value = 0.0063.
(C) Histograms detailing the differences of H3K27me3 patterns between hESC and fibroblasts, measured as the Euclidean distance across the sixteen 500 bp
regions of the promoters for the indicated gene sets. The black outlined bars denote the distribution of Euclidean distances for all genes on the array (17,000),
while the red outlined bars show the distribution for the indicated subset of signature genes.
(D) As in (C) but for histone H3K4 trimethylation. Note: hESC signature genes must undergo a significantly larger degree of change in both H3K4me3 (**p value =
0.005) and H3K27me3 (***p < 107) than the global population of genes. None of the distributions for the other subsets of genes are significantly different from the
global population.Hierarchical clusteringwith the 105miRNAs expressed in at least
one cell type shows that there is little difference in miRNA
expression among the pluripotent cells tested with hiPSCs and
hESCs intermixed in the tree of the clustering. Conversely, all
of the pluripotent cell lines have a vastly different miRNA profile
than fibroblasts. Nevertheless, a few miRNAs were consistently118 Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc.expressed differently between late hiPSCs and hESCs (Fig-
ure 5B). This finding was similar to data recently obtained by
another group that also profiled the miRNA expression profile
of different lines of a different set of hESCs and hiPSCs (high-
lighted miRNAs in Figure 5B [Wilson et al., 2009]), suggesting
that a distinct miRNA pattern is highly reproducible between
Cell Stem Cell
Expression Signatures Distinguish iPSCs from hESCsFigure 5. MicroRNA Expression Analysis in hESC, l-hiPSC, and Fibroblast Lines
(A) Hierarchical clustering of the expression data for the 105 microRNAs substantially expressed in either hESCs (H9 and HSF1), l-hiPSCs (lines 1, 2, and 18), or
fibroblasts, given as log2 ratios relative to expression in fibroblasts. Note: miRNA expression does not cluster the hESC lines distinctly from the hiPSC lines,
whereas the fibroblasts, as expected, exhibit a different miRNA expression pattern.
(B) Table showingmiRNAs that were differentially expressed between the two hESC lines (12 replicates total) and three l-hiPSC lines (15 replicates total). Expres-
sion values for the given cell lines are given aswell as the p value derived from the Student’s t test. Asterisk indicates thatmiRNAwas also found to be differentially
expressed between hESC and hiPSC lines in Wilson et al. (2009).different reprogramming experiments, and that hiPSCs have
a miRNA signature that defines them as unique from hESCs.
An Analysis of the Genomic Stability of hiPSCs
Apriori, the cause of the differential expression of genes between
hiPSC and hESC could be that the reprogramming protocol
itself requires or leads to genomic alterations. It has been sug-
gested that, because reprogramming efficiency is low and
because exogenous expression mediated by retrovirus requires
genomic integration, reprogramming perhaps is accompanied
by genomic alterations. With the advent of integration-free
reprogramming, many of these concerns are probably not valid
(Kaji et al., 2009; Soldner et al., 2009; Stadtfeld et al., 2008; Wolt-
jen et al., 2009; Yu et al., 2009). Regardless, the genomic stability
of both miPSCs and hiPSCs had not been examined after
extendedpassaging by any techniquemore sensitive than karyo-
typing.Many groups, including ours, showed that reprogrammed
lines usually have a normal karyotype (Lowry et al., 2008), but it
has remained formally possible that subkaryotypic alterations
accompany reprogramming. It is also possible that hiPSCs could
have an unstable genome, prone to alteration due to some
unknown byproduct of the reprogramming process. To date, no
one has yet profiled iPSCs from any species to resolve these
issues, which could prove critical in the application of iPSC tech-
nology to regenerative medicine.
To determine systematically whether our hiPSC lines contain
genomic alterations that could possibly explain the differences
in gene expression between hESCs and hiPSCs, array compar-
ative genomic hybridization (aCGH) was performed on three
hiPSC lines and the fibroblasts from which they were derived.Using Human CGH Tiling Arrays (NimbleGen, Roche), a few sub-
karyotypic alterationswere detected in each late-passage hiPSC
line relative to the starting fibroblast line (Table 1; Figure S15). As
confirmation of the validity of the approach, the duplication of
part of chromosome 8 in the hiPSC line 1 identified by array
CGH had already been discovered by karyotyping at p44
(Figure 6A). hiPSC line 1 must have acquired this duplication of
part of chromosome 8 upon extended passaging, as it was not
detected at p9 (Lowry et al., 2008).
Interestingly, none of the genomic alterations detected by
aCGH appeared to be shared among all three hiPSC lines
(Figure 6B; Table 1), leading to two conclusions: (1) no particular
genomic alteration is required for reprogramming; (2) these
genomic alterations cannot directly explain the early hiPSC
signature because the signature strictly represents changes
found in all three lines. Genes harbored in genomic regions
that are altered in hiPSCs are significantly enriched for lipocalins
and serine proteases (in hiPSC 18), tumor antigens (hiPSC 2),
and lectins, keratins, and sensory transduction (hiPSC 1), with
none of these functional classifications being conserved
between two different hiPSC lines. Regardless, these analyses
suggest that the genome of reprogrammed cells is both normal
and highly stable even after at least 44 passages.
DISCUSSION
While there is still much to learn about themolecular details of the
iPSC state, our data indicate that early- and late-passage
hiPSCs are not identical to their embryo-derived counterparts.
Many groups have generated iPSCs from both human andCell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 119
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Chromosome Cell Line Identified Region Size Z-Score
Mean (log2ratio) Fibroblast/
hiPSC No. of Genes No. of miRNA
7p11.2 hiPSC2 56808738-62112547 5.3 Mb 19.37 0.213 1 0
8q12.3 hiPSC1 62203767-100955803 83.8 Mb 45.26 0.185 148 3
9q34.3 hiPSC2 137714842-139627239 1.9 Mb 21.60 0.207 75 1
hiPSC18 135323818-139634573 4.3 Mb 21.38 0.138 102 1
10q21.3 hiPSC2 67642045-67930512 0.3 Mb 19.24 0.473 1 0
11p11.12 hiPSC2 48381190-55253892 6.9 Mb 19.24 0.149 16 0
12p13.31 hiPSC1 62119-11760562 11.7 Mb 45.32 0.175 176 2
14q32.33 hiPSC2 103616693-106182502 2.6 Mb 19.71 0.163 27 1
hiPSC18 103353890-106222351 2.9 Mb 18.12 0.141 30 1
16p13.3 hiPSC2 7675-2208335 2.2 Mb 19.30 0.172 104 2
hiPSC18 53-2234072 2.2 Mb 20.49 0.181 107 2
19p13.3 hiPSC2 208435-2449396 2.2 Mb 24.08 0.213 86 2
hiPSC18 40285-3774141 3.7 Mb 24.35 0.170 121 2
20q13.33 hiPSC18 59860004-62429688 2.6 Mb 18.50 0.154 81 7
21q22.3 hiPSC1 38084180-46913738 8.8 Mb 73.43 0.320 144 0
22q13.32 hiPSC2 46997532-49534378 2.5 Mb 21.66 0.177 37 0
hiPSC18 40986242-49567312 8.6 Mb 22.54 0.100 103 3
Xq21.1 hiPSC1 77883731-90950867 13.1 Mb 20.61 0.080 30 2
hiPSC2 25192507-151731387 126.5 Mb 31.42 0.122 714 69
Yp11.2-q11.21 hiPSC2 2858143-20250487 17.4 Mb 28.19 0.120 27 0mouse somatic cells, and each group suggested that their iPSCs
were ‘‘nearly’’ identical to the ESCs they used for comparison.
Until now, it was not clear if the small differences observed in
gene expression between iPSCs and ESCs were due to
stochastic differences in each experiment, or whether all reprog-
rammed cells share a signature that distinguishes them from
ESCs. Reanalyzing hiPSCs and miPSCs suggests that in fact
all iPSCs share a gene expression signature that defines the
iPSC state as unique from that of ESCs.
The gene expression signature observed in early-passage
hiPSCs seems to be partially corrected upon extended culturing
in vitro, suggesting that perhaps some form of ‘‘reprogramming’’
continues in culture. This could be due to feed-forward or feed-
back loops of gene regulation under the direction of the
Figure 6. Genomic Abnormalities Are Not
Conserved among l-hiPSC Lines
(A) Karyotype analysis of the only genomic abnor-
mality detected in any of our hiPSC lines. A clonal
duplication on chromosome 8 was found in 19 of
20 metaphase spreads in hiPSC line 1 at passage
44. Array CGH also identified this region (Z-score =
45) solely in the hiPSC1 line (see Table 1), and the
array CGH data for this region in all hiPSC lines
and fibroblasts are given. The duplicated region
in hiPSC1 ‘‘steps’’ down from the midline, indi-
cated by the red box.
(B) A cartoon schematic depicting all overlapping
genomic abnormalities among hiPSC lines that
were determined by array CGH. Alterations in
l-hiPSC1 are indicated with green bars, in
l-hiPSC2 with blue bars, and in l-hiPSC18 with
red bars. These six regions were the only ones
found to be shared between any two hiPSC lines.
No genomic aberrations were found in all three
l-hiPSC lines.120 Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc.
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Young, 2008). Moreover, since low-passage hESCs did not
appear to share the early-passage hiPSC signature, it seems as
though this extended reprogramming phase is not simply due
to the time a pluripotent cell spent in culture, but something
more specific to iPSCs. While late-passage hiPSCs appeared
to be much more similar to their embryo-derived counterparts
with regard tomostof the transcriptome (includingcodingandmi-
croRNA), there is a group of genes and miRNAs that are differen-
tially expressed compared to hESCs. For the most part, these
differences reflect either an insufficient induction of ESC genes
or insufficient suppression of fibroblast genes. Together, these
findings suggest that the reprogramming process does not drive
fibroblasts to a state identical to ESCs.
Reprogramming Is Not Perfect
It is not surprising that iPSCs are not perfectly identical to ESCs
considering the vastly different set of circumstances by which
they were generated. ESCs are derived from the inner cell mass
of an embryo and are thought to undergo significant changes
as they adapt to in vitro culture. However, mESCs can be placed
back into a blastocyst and contribute to the resulting offspring
even at 100%, suggesting that the changes induced by in vitro
culture either are not fate changing or are reversible. Of course,
it is far more difficult to compare hESCs to the cells of the inner
cell mass from which they were derived in order to understand
their origins, for technical and ethical reasons. Regardless, it is
clear that iPSCs arise by a markedly different mechanism. iPSCs
start out as fully determined somatic cells. These somatic cells
possess nuclei that are almost completely refractory to repro-
gramming, as demonstrated by the low efficiency of cloning by
somatic cell nuclear transfer (Gurdon andMelton, 2008;Markou-
laki et al., 2008) or of reprogramming with the four Yamanaka
factors (Takahashi and Yamanaka, 2006). Therefore, a drastic
molecular change is presumably essential to reset the somatic
nucleus to an embryonic/pluripotent state.
A great deal of effort is underway to understand the role each of
the reprogramming factors plays during the process, beginning
withdocumentationof thecompleteset of targetgenesatdifferent
stages (Sridharan et al., 2009). Considering all the changes to the
transcriptome, epigenome, metabolome, and proteome that are
likely required for reprogramming, it should come as no surprise
that reprogramming somatic cells with four transcription factors
does not perfectly recapitulate the state of ESCs. The data pre-
sented here describe the deficits of reprogramming with regards
to just portions of the transcriptome and epigenome. It is likely
that thereare a numberof other fundamentalmolecular character-
istics that distinguish iPSCs from ESCs. Even though not tested
extensively, one of the functional manifestations of these differ-
ences could be that miPSCs have not yet been shown to support
the generation of adult mice that are completely derived from
these cells.
Do Errors in Epigenetic Reprogramming
Generate the iPSC State?
We next considered whether the iPSC state arises because of
defective resetting and/or re-establishment of the epigenome
that is thought to occur during reprogramming (Maherali et al.,
2007; Takahashi et al., 2007; Wernig et al., 2007). Clearly, fibro-blast and ESC epigenomes are maintained in very different
states, ostensibly to help control gene expression, differentiation
potential, self-renewal, etc. There are data to suggest that when
fibroblasts are reprogrammed, the histone code is dramatically
altered, whereby modifications that are known to correlate with
gene silencing are removed from pluripotency genes and
replaced by those that mark active genes and vice versa (Maher-
ali et al., 2007). Here, we examined which promoters were asso-
ciated with a histone mark that is well established to be linked
to gene silencing in fibroblasts, hESCs, and hiPSCs. Overall,
hiPSCs and hESCs had a very similar pattern of H3K27 trimethy-
lation of promoter regions, and this pattern was strikingly
different from fibroblasts. The promoters of the late hiPSC signa-
ture genes appeared to have a H3K27 trimethylation pattern
similar to that found in hESCs. These data suggested that the
late hiPSC signature does not arise as a result of aberrant reset-
ting of these histone methylation marks. Of course, there are
a multitude of various types and combinations of histone modi-
fications, many of which are known to be associated with active
or silenced genes, so any of these others might yet explain the
presence of the late hiPSC expression signature. Recently, Gur-
don and colleagues suggested, for example, that the histone
variant H3.3 is a carrier of an epigenetic memory in frog cloning
experiments (Ng and Gurdon, 2008).
Are hESCs and hiPSCs More Similar in Their
Noncoding RNA Expression?
Recent data suggest that most cell types express a unique
pattern of noncoding RNAs such as miRNAs (Laurent et al.,
2008). miRNAs are known to suppress expression of their homol-
ogous target RNAs through the association with the RISC
complex (RNA-induced silencing complex) (Tang, 2005). miRNA
expression profiles are known to change as tissues develop and
individual cells differentiate (Krutzfeldt et al., 2006; Yi et al., 2006,
2008, 2009). Profiling the expression of miRNAs in undifferenti-
ated hESCs, hiPSCs, and fibroblasts demonstrated a vast differ-
ence in expression of at least 100 miRNAs between these two
pluripotent populations and fibroblasts. A handful of miRNAs
are significantly different in expression between hESCs and
hiPSCs. Most of these miRNAs were also described as differen-
tially expressed between hESCs and hiPSCs in an independent
experiment with independently derived hESCs and hiPSCs (Wil-
son et al., 2009). Importantly, hiPSCs in this study were derived
by overexpression of the Thomson set of reprogramming factors
replacing c-MYC and KLF4 with NANOG and LIN28. Since each
miRNA is known to have multiple targets, it is formally possible
that even the 10 to 12 miRNAs shown to be differentially
expressed between hESCs and hiPSCs could explain the occur-
rence of the late hiPSC signature. However, because in silico
miRNA target prediction has not been perfected, future efforts
will be required to uncover the contribution of differential expres-
sion of these miRNAs to the late hiPSC signature. In any case,
it is interesting that some of the miRNAs that are differentially
expressed between hiPSC and hESCs include a group of
ESC-specific miRNAs (Card et al., 2008). Furthermore, the
miR-302 and miR-371/372/373 clusters encode the human
homologs of the mouse 290–295 cluster, which are indicated
as enhancers of the reprogramming process (Judson et al.,
2009). Cleary, further study will be required to elucidate theCell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 121
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process and the maintenance of the iPSC state.
Consequences of the iPSC State
The results described here suggest that hiPSCs represent
a unique type of pluripotent cell as defined by gene expression.
What are the physiological consequences of the variance? To
date, no one has described significant functional differences
between hiPSCs and hESCs. Many groups have shown that
hiPSCs are pluripotent by embryoid body and teratoma forma-
tion assays (Lowry et al., 2008; Park et al., 2008; Takahashi
et al., 2007; Yu et al., 2007). Of course, several gold-standard
assays of pluripotency used for mouse pluripotent cells cannot
be performed with human equivalents (chimerism, germline
transmission), so it is not possible to judge the relative pluripo-
tency of hiPSCs and hESCs. Some groups have described small
differences between hiPSCs and hESCs in their relative abilities
to undergo directed differentiation (Choi et al., 2009; Karum-
bayaram et al., 2009; Zhang et al., 2009). However, because of
the inherent biases among pluripotent cell lines to adopt partic-
ular fates, it is unclear whether there are any general differences
between hiPSCs and hESCs in this regard (Osafune et al., 2008).
Additionally, there are no published data to suggest that hiPSCs
and hESCs function differently in the undifferentiated state. The
molecular differences between iPSCs and ESCs described here
should drive intense effort in the future aimed at uncovering any
possible physiological consequences.
EXPERIMENTAL PROCEDURES
Tissue Culture
Cells were cultured as described in Lowry et al. (2008).
Gene Expression Analysis
Gene expression profiling was performed as described (Lowry et al., 2008). All
human expression data from this experiment and those conducted in other
labs were obtained with the HG-U133plus2 microarray platform (Affymetrix).
Mouse expression data were extracted fromMaherali et al. (2007) and Mikkel-
sen et al. (2008), both using theMouse Expression Array 430 platform (Affyme-
trix). For analyses, the array data for fibroblasts, ESCs, and iPSCs were
normalized independently for each experiment using Robust Multichip Anal-
ysis (RMA) in R (Bioconductor). Expression data for each gene were obtained
from respective probe sets utilizing a hierarchical averaging algorithm. Specif-
ically, exponent expression values were averaged for individual RefSeq iden-
tifiers based on the specificity of the probes assigned to each RefSeq. If
multiple ‘‘_at’’ probes existed for RefSeq gene X, then those probes were aver-
aged. If no specific probes existed for that RefSeq, then the next level ‘‘_a_at’’
probes were used. This filtering continued until the highest-confidence probes
were chosen to represent each RefSeq, thereby ensuring that analysis was
specific to each gene. The resulting human and mouse data sets contain
17,620 and 16,330 genes, respectively. 11,975 homologous genes were sepa-
rated for direct comparison between the human and mouse data sets as
curated by the Homologene database. All cell line correlations were ameasure
of Pearson’s rho implemented in R. Significance of overlap between any two
data sets was measured using Fisher’s exact test. Significance of the overlap
of the three human data sets was measured using simulation with replace-
ment. Global array clustering was performed using Cluster 3.0 and presented
using Java Treeview 1.1.1 with gene expression values presented as a log2
ratio compared to averaged ESC expression. Class prediction was conducted
using Student’s t test combined with a requirement for a 1.5-fold change
between the average of the cell lines being compared. Boxplots were created
in R, and differences observed were assigned significance values using the
Wilcoxon rank-sum test.122 Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc.miRNA Expression Analysis
miRNA expression analysis was conducted as described (Zhang et al., 2008)
using the Ohio State University Comprehensive Cancer Center (OSUCCC)
miRNA Expression Bioarrays.
Histone Methylation Analysis
Genome-wide chromatin analysis was performed as described (Maherali et al.,
2007).
aCGH Methods
Genomic DNA from cell lines with indicated passages was collected and puri-
fied using QIAGEN DNA kit (QIAGEN, Germany). Hybridization was conducted
with Human CGH 2.1M Whole-Genome-Tiling v2.0D Array (NimbleGen), with
a resolution of 5 kb over the entire human genome. Hybridization and raw
data collection were performed as described in Selzer et al. (2005).
CGH Analysis Methods
Raw signal intensities for Cy3 and Cy5 were extracted from each array. Inten-
sity values were averaged for the three replicate probes. Log ratios of the
average values were generated for each of the two dyes. Each array was
normalized by subtracting from each individual probe themean log ratio values
over all probes in the array. Regions were computed along the chromosome
that had elevated average values, possibly representing copy number varia-
tion (CNV). All possible windows were computed within the chromosome,
and for each window computed a Z-score. Because of computational limita-
tions, each chromosome was segmented into pieces corresponding to 3000
probes, leading to a potential overestimation of the number of CNV regions
if these span the boundaries across two chunks, since they would then be
considered two separate CNVs. Based on random permutations of the array
probes, we established that a Z-score of 18 for a region containing more
than five probes provides a false-positive rate of less than 1%. The code
was implemented in Matlab.
ACCESSION NUMBERS
Microarray and ChIP-chip array data are available at the NCBI Gene Expres-
sion Omnibus database under the accession numbers GSE12390, 7815,
14012, 9865, 14711, 15176, and 16654.
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Supplemental Data include six tables and 15 figures and can be found with
this article online at http://www.cell.com/cell-stem-cell/supplemental/S1934-
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ACKNOWLEDGMENTS
M.H.C. is supported by the USHHS Ruth L. Kirschstein Institutional (NRSA
#T32CA009056) andG.A. byNIH/NICHHD 5K12HD001281. S.V. is supported
by Regione Emilia Romagna PRRIITT Biopharmanet. C.M.C. is supported by
NIH-NCI.M.A.T. is supported byNIH andCIRMGrant RS1-00313.M.G. is sup-
ported by NIH GM23674. N.B. is supported by the Legacy Heritage Fund. K.P.
is supported by the V and Kimmel Scholar Foundations, the NIH Director’s
Young Innovator Award (DP2 OD001686-01), and a CIRM Young Investigator
Award (RN1-00564-1). W.E.L. holds the Maria Rowena Ross Term Chair in
Cell Biology and Biochemistry and is supported by CIRM #RS1-00259-1, and
the Basil O’Connor Starter Scholar Award from The March of Dimes. This
work was also supported by the CIRM New Cell Line grant to Jerome Zack
(UCLA), W.E.L., and K.P. (RL1-00681-1). A.T.C., A.D.P., K.P., and M.A.T. are
also supported by NIH P01 GM081621-01A1.
Received: March 28, 2009
Revised: May 30, 2009
Accepted: June 12, 2009
Published: July 1, 2009
Cell Stem Cell
Expression Signatures Distinguish iPSCs from hESCsREFERENCES
Cao, R., and Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methyla-
tion of lysine 27 in histone H3. Curr. Opin. Genet. Dev. 14, 155–164.
Card, D.A., Hebbar, P.B., Li, L., Trotter, K.W., Komatsu, Y., Mishina, Y., and
Archer, T.K. (2008). Oct4/Sox2-regulated miR-302 targets cyclin D1 in human
embryonic stem cells. Mol. Cell. Biol. 28, 6426–6438.
Choi, K.D., Yu, J., Smuga-Otto, K., Salvagiotto, G., Rehrauer, W., Vodyanik,
M., Thomson, J., and Slukvin, I. (2009). Hematopoietic and endothelial differ-
entiation of human induced pluripotent stem cells. Stem Cells 27, 559–567.
Gokhale, P.J., and Andrews, P.W. (2006). A prospective on stem cell research.
Semin. Reprod. Med. 24, 289–297.
Gurdon, J.B., and Melton, D.A. (2008). Nuclear reprogramming in cells.
Science 322, 1811–1815.
Hochedlinger, K., and Plath, K. (2009). Epigenetic reprogramming and induced
pluripotency. Development 136, 509–523.
Jaenisch, R., and Young, R. (2008). Stem cells, the molecular circuitry of
pluripotency and nuclear reprogramming. Cell 132, 567–582.
Judson, R.L., Babiarz, J.E., Venere, M., and Blelloch, R. (2009). Embryonic
stem cell-specific microRNAs promote induced pluripotency. Nat. Biotechnol.
27, 459–461.
Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., and Woltjen, K.
(2009). Virus-free induction of pluripotency and subsequent excision of
reprogramming factors. Nature 458, 771–775.
Karumbayaram, S., Novitch, B.G., Patterson, M., Umbach, J.A., Richter, L.,
Lindgren, A., Conway, A., Clark, A., Goldman, S.A., Plath, K., et al. (2009).
Directed differentiation of human induced-pluripotent stem cells generates
active motor neurons. Stem Cells 27, 806–811.
Keller, G. (2005). Embryonic stem cell differentiation: emergence of a new era
in biology and medicine. Genes Dev. 19, 1129–1155.
Krutzfeldt, J., Poy, M.N., and Stoffel, M. (2006). Strategies to determine the
biological function of microRNAs. Nat. Genet. 38 (Suppl ), S14–S19.
Laurent, L.C., Chen, J., Ulitsky, I., Mueller, F.J., Lu, C., Shamir, R., Fan, J.B.,
and Loring, J.F. (2008). Comprehensive microRNA profiling reveals a unique
human embryonic stem cell signature dominated by a single seed sequence.
Stem Cells 26, 1506–1516.
Lowry, W.E., Richter, L., Yachechko, R., Pyle, A.D., Tchieu, J., Sridharan, R.,
Clark, A.T., and Plath, K. (2008). Generation of human induced pluripotent
stem cells fromdermal fibroblasts. Proc. Natl. Acad. Sci. USA 105, 2883–2888.
Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., Stadtfeld,
M., Yachechko, R., Tchieu, J., Jaenisch, R., et al. (2007). Directly reprog-
rammed fibroblasts show global epigenetic remodeling and widespread tissue
contribution. Cell Stem Cell 1, 55–70.
Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J., Cowan, C., and Hochedlin-
ger, K. (2008). A high-efficiency system for the generation and study of human
induced pluripotent stem cells. Cell Stem Cell 3, 340–345.
Markoulaki, S., Meissner, A., and Jaenisch, R. (2008). Somatic cell nuclear
transfer and derivation of embryonic stem cells in the mouse. Methods 45,
101–114.
Mikkelsen, T.S., Hanna, J., Zhang, X., Ku, M., Wernig, M., Schorderet, P.,
Bernstein, B.E., Jaenisch, R., Lander, E.S., andMeissner, A. (2008). Dissecting
direct reprogramming through integrative genomic analysis. Nature 454,
49–55.
Ng, R.K., and Gurdon, J.B. (2008). Epigenetic memory of an active gene state
depends on histone H3.3 incorporation into chromatin in the absence of tran-
scription. Nat. Cell Biol. 10, 102–109.
Nishikawa, S., Goldstein, R.A., and Nierras, C.R. (2008). The promise of human
induced pluripotent stem cells for research and therapy. Nat. Rev. Mol. Cell
Biol. 9, 725–729.
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-
competent induced pluripotent stem cells. Nature 448, 313–317.
Osafune, K., Caron, L., Borowiak, M., Martinez, R.J., Fitz-Gerald, C.S., Sato,
Y., Cowan, C.A., Chien, K.R., and Melton, D.A. (2008). Marked differencesin differentiation propensity among human embryonic stem cell lines. Nat.
Biotechnol. 26, 313–315.
Park, I.H., Zhao, R., West, J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H.,
Lensch, M.W., and Daley, G.Q. (2008). Reprogramming of human somatic
cells to pluripotency with defined factors. Nature 451, 141–146.
Park, T.S., Galic, Z., Conway, A.E., Lindgren, A., Van Handel, B.J., Magnus-
son, M., Richter, L., Teitell, M.A., Mikkola, H., Lowry, W.E., et al. (2009). Deri-
vation of primordial germ cells from human embryonic and induced pluripotent
stem cells is significantly improved by coculture with human fetal gonadal
cells. Stem Cells 27, 783–795.
Selzer, R.R., Richmond, T.A., Pofahl, N.J., Green, R.D., Eis, P.S., Nair, P.,
Brothman, A.R., and Stallings, R.L. (2005). Analysis of chromosome break-
points in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucle-
otide array CGH. Genes Chromosomes Cancer 44, 305–319.
Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Har-
gus, G., Blak, A., Cooper, O., Mitalipova, M., et al. (2009). Parkinson’s disease
patient-derived induced pluripotent stem cells free of viral reprogramming
factors. Cell 136, 964–977.
Sridharan, R., Tchieu, J., Mason, M.J., Yachechko, R., Kuoy, E., Horvath, S.,
Zhou, Q., and Plath, K. (2009). Role of the murine reprogramming factors in
the induction of pluripotency. Cell 136, 364–377.
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008).
Induced pluripotent stem cells generated without viral integration. Science
322, 945–949.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K.,
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human
fibroblasts by defined factors. Cell 131, 861–872.
Tang, G. (2005). siRNA and miRNA: an insight into RISCs. Trends Biochem.
Sci. 30, 106–114.
Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger,
K., Bernstein, B.E., and Jaenisch, R. (2007). In vitro reprogramming of fibro-
blasts into a pluripotent ES-cell-like state. Nature 448, 318–324.
Wilson, K.D., Venkatasubrahmanyam, S., Jia, F., Sun, N., Butte, A.J., and Wu,
J.C. (2009). MicroRNA profiling of human-induced pluripotent stem cells. Stem
Cells Dev. 18, 749–758.
Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen,
R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009). piggyBac
transposition reprograms fibroblasts to induced pluripotent stem cells. Nature
458, 766–770.
Yi, R., O’Carroll, D., Pasolli, H.A., Zhang, Z., Dietrich, F.S., Tarakhovsky, A.,
and Fuchs, E. (2006). Morphogenesis in skin is governed by discrete sets of
differentially expressed microRNAs. Nat. Genet. 38, 356–362.
Yi, R., Poy, M.N., Stoffel, M., and Fuchs, E. (2008). A skin microRNA promotes
differentiation by repressing ‘stemness’. Nature 452, 225–229.
Yi, R., Pasolli, H.A., Landthaler, M., Hafner, M., Ojo, T., Sheridan, R., Sander,
C., O’Carroll, D., Stoffel, M., Tuschl, T., et al. (2009). DGCR8-dependent micro-
RNA biogenesis is essential for skin development. Proc. Natl. Acad. Sci. USA
106, 498–502.
Yu,J., Vodyanik,M.A.,Smuga-Otto,K.,Antosiewicz-Bourget, J.,Frane,J.L.,Tian,
S.,Nie, J.,Jonsdottir,G.A.,Ruotti,V.,Stewart,R., etal. (2007). Inducedpluripotent
stem cell lines derived from human somatic cells. Science 318, 1917–1920.
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I., and Thomson, J.
(2009). Human induced pluripotent stem cells free of vector and transgene
sequences. Science 324, 797–801.
Zhang, L., Volinia, S., Bonome, T., Calin, G.A., Greshock, J., Yang, N., Liu,
C.G., Giannakakis, A., Alexiou, P., Hasegawa, K., et al. (2008). Genomic and
epigenetic alterations deregulate microRNA expression in human epithelial
ovarian cancer. Proc. Natl. Acad. Sci. USA 105, 7004–7009.
Zhang, J., Wilson, G.F., Soerens, A.G., Koonce, C.H., Yu, J., Palecek, S.P.,
Thomson, J.A., and Kamp, T.J. (2009). Functional cardiomyocytes derived
from human induced pluripotent stem cells. Circ. Res. 104, e30–e41.Cell Stem Cell 5, 111–123, July 2, 2009 ª2009 Elsevier Inc. 123
